EGFR and non-small cell lung carcinoma: In the WJTOG3405 phase III trial, 177 chemotherapy-naïve, EGFR mutated (either exon 19 deletion or L858R point mutation), advanced NSCLC patients from 36 centers in Japan were randomly assigned to receive either gefitinib or cisplatin plus docetaxel for three to six cycles.